What coverage limits does clinical trial liability insurance require?

There is no single clinical trial liability limit. The right number is set by the trial's risk - how novel the intervention is, how sick the population is, how many subjects are enrolled, and where the trial runs. Sponsors set a baseline limit and then adjust upward for higher-risk studies; ethics committees and some national regulators impose their own minimums.

Two structures appear in most programs: an aggregate limit for the whole trial, and - increasingly - a per-subject or per-claimant sub-limit. Both matter: a single catastrophic subject injury tests the per-claimant figure, while a systemic issue affecting many subjects tests the aggregate.

Trial phase: first-in-human and early-phase (Phase I) studies carry the highest per-subject uncertainty and often demand the highest limits relative to subject count; later-phase (III) studies spread risk across more subjects but raise the aggregate exposure.

Indication and population: oncology, rare-disease, pediatric, gene/cell therapy, and studies in vulnerable populations push limits up because the severity and novelty of potential injury is higher.

Subject count and geography: more subjects raise the aggregate; multi-country trials must satisfy the highest applicable national requirement. Several countries (and some EU member states) impose statutory minimum trial-insurance limits that can exceed the sponsor's default.

For US interventional trials, aggregate limits commonly fall in the $5M-$10M range, with lower-risk observational or late-phase studies sometimes acceptable at lower limits and high-risk early-phase, oncology, or first-in-human studies frequently requiring $10M or more. These are practitioner-typical ranges, not regulatory mandates - the controlling number is whatever the CTA, the IRB, and any applicable national law specify for the particular study.

Where a per-subject sub-limit is used, it is set so that a single severe subject injury can be fully funded without exhausting the aggregate that protects the rest of the cohort.

The clinical trial agreement between sponsor and site (or sponsor and CRO) specifies the required trial liability limit, who carries it, subject-injury/compensation obligations, and indemnification. The IRB or ethics committee reviews the insurance and subject-compensation arrangements as part of approving the study - inadequate limits can hold up approval and enrollment.

For multi-site or multi-country trials, the sponsor typically sets a master limit and then tops up where a site's jurisdiction requires more. A site or CRO negotiating a CTA should confirm whether it is expected to carry its own trial liability tower or rely on the sponsor's master policy, and at what limit.

Clinical trial liability is one line in the program. It pairs with professional liability (E&O) for the service exposure, general liability for ordinary third-party claims, and frequently an umbrella/excess tower when a sponsor MSA specifies a combined limit. Sizing the trial liability correctly without confirming the umbrella and E&O limits the same contract requires is a common gap - the CTA's insurance schedule should be read as a whole.